New hope for advanced cancers: JAB-8263 enters human testing
NCT ID NCT04686682
First seen Jan 10, 2026 · Last updated May 18, 2026 · Updated 19 times
Summary
This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.